Semax has been clinically approved in Russia for over 30 years for stroke and cognitive disorders, yet remains largely unknown in Western research circles. The compound's BDNF-upregulating mechanism, genome-wide ischemia transcriptome data, and three decades of clinical use make it one of the most substantively researched nootropic peptides available.